MBX Biosciences Company Insiders
| MBX Stock | 31.54 0.64 2.07% |
MBX Biosciences employs about 43 people. The company is managed by 12 executives with a total tenure of roughly 101 years, averaging almost 8.0 years of service per executive, having 3.58 employees per reported executive. Break down of MBX Biosciences' management performance can provide insight into the company performance.
MBX Biosciences Management Team Effectiveness
The company has Return on Asset of (0.1664) % which means that on every $100 spent on assets, it lost $0.1664. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.2443) %, meaning that it generated no profit with money invested by stockholders. MBX Biosciences' management efficiency ratios could be used to measure how well MBX Biosciences manages its routine affairs as well as how well it operates its assets and liabilities.The majority of MBX Biosciences outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in MBX Biosciences Common to benefit from reduced commissions. Therefore, institutional holders are subject to a different set of regulations than regular investors in MBX Biosciences Common. Please pay attention to any change in the institutional holdings of MBX Biosciences as this could imply that something significant has changed or is about to change at the company.
Some institutional investors establish a significant position in stocks such as MBX Biosciences in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of MBX Biosciences, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
MBX Biosciences Workforce Comparison
MBX Biosciences Common is rated below average in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 3,367. MBX Biosciences claims roughly 43.0 in number of employees contributing just under 2% to equities under Health Care industry.
MBX Biosciences Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific MBX Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on MBX Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, MBX Biosciences insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Steven Hoerter over a month ago Acquisition by Steven Hoerter of 8000 shares of MBX Biosciences, at 27.08 subject to Rule 16b-3 | ||
Hawryluk P. Kent over two months ago Disposition of 182859 shares by Hawryluk P. Kent of MBX Biosciences, at 3.25 subject to Rule 16b-3 | ||
Hoerter Steven L. over two months ago Acquisition by Hoerter Steven L. of 20000 shares of MBX Biosciences, at 13.2492 subject to Rule 16b-3 | ||
Pescovitz Ora H. over six months ago Acquisition by Pescovitz Ora H. of 16000 shares of MBX Biosciences, at 11.86 subject to Rule 16b-3 | ||
Pescovitz Ora H. over six months ago Acquisition by Pescovitz Ora H. of 7693 shares of MBX Biosciences, at 5.89 subject to Rule 16b-3 | ||
Hoerter Steven L. over six months ago Insider Trading |
MBX Biosciences Notable Stakeholders
A MBX Biosciences stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as MBX Biosciences often face trade-offs trying to please all of them. MBX Biosciences' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting MBX Biosciences' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Peter MBA | President CEO | Profile | |
| Michelle Graham | Chief Officer | Profile | |
| Dr DABT | Vice Development | Profile | |
| Salomon MD | Chief Officer | Profile | |
| Andreas MD | Senior Development | Profile | |
| Mark Hope | Senior Quality | Profile | |
| Steven Hoerter | Executive Chairperson | Profile | |
| Salomon Azoulay | Chief Officer | Profile | |
| Chatan Charan | Manufacturing Chemistry | Profile | |
| MBA MBA | Chief Officer | Profile | |
| Matt Gambino | Vice Marketing | Profile | |
| Richard CPA | Chief Officer | Profile |
About MBX Biosciences Management Performance
The success or failure of an entity such as MBX Biosciences Common often depends on how effective the management is. MBX Biosciences management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of MBX management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the MBX management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Please note, the imprecision that can be found in MBX Biosciences' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of MBX Biosciences Common. Check MBX Biosciences' Beneish M Score to see the likelihood of MBX Biosciences' management manipulating its earnings.
MBX Biosciences Workforce Analysis
Traditionally, organizations such as MBX Biosciences use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare MBX Biosciences within its industry.MBX Biosciences Manpower Efficiency
Return on MBX Biosciences Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 1.4M | |
| Net Loss Per Executive | 5.2M | |
| Working Capital Per Employee | 6M | |
| Working Capital Per Executive | 21.4M |
Additional Tools for MBX Stock Analysis
When running MBX Biosciences' price analysis, check to measure MBX Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MBX Biosciences is operating at the current time. Most of MBX Biosciences' value examination focuses on studying past and present price action to predict the probability of MBX Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MBX Biosciences' price. Additionally, you may evaluate how the addition of MBX Biosciences to your portfolios can decrease your overall portfolio volatility.